Publications by authors named "Marc S Sabatine"

100Publications

Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.

J Thromb Thrombolysis 2020 Jul 18. Epub 2020 Jul 18.

TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-020-02221-5DOI Listing
July 2020

The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.

Circulation 2020 Aug 19;142(6):538-545. Epub 2020 Jun 19.

TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.046251DOI Listing
August 2020

Cognition After Lowering LDL-Cholesterol With Evolocumab.

J Am Coll Cardiol 2020 May;75(18):2283-2293

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2020.03.039DOI Listing
May 2020

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.

Stroke 2020 May 21;51(5):1546-1554. Epub 2020 Apr 21.

From the TIMI (Thrombolysis in Myocardial Infarction) Study Group, Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (R.P.G., E.A.B., S.A.M., M.S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.119.027759DOI Listing
May 2020

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.

Circulation 2020 May 29;141(20):1600-1607. Epub 2020 Mar 29.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., Y.G., G.E.M.M., B.G., M.L.O., R.P.G., C.T.R., M.S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.046397DOI Listing
May 2020

Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.

J Am Coll Cardiol 2020 Mar;75(10):1095-1106

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.12.067DOI Listing
March 2020

Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.

Diabetes Obes Metab 2020 Jul 12;22(7):1122-1131. Epub 2020 Mar 12.

Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.14011DOI Listing
July 2020

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial.

Eur J Prev Cardiol 2020 Feb 4:2047487320902750. Epub 2020 Feb 4.

TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2047487320902750DOI Listing
February 2020

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.

Circulation 2020 Apr 27;141(15):1227-1234. Epub 2020 Jan 27.

TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (T.A.Z., M.P.B., R.H.M.F., J.F.K., S.A.M., D.L.B., M.S.S., S.D.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044183DOI Listing
April 2020

Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography.

J Am Coll Cardiol 2020 01;75(3):289-300

Thrombosis In Myocardial Infarction Study Group-Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.11.035DOI Listing
January 2020

Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes.

J Am Coll Cardiol 2019 12 9;74(24):3013-3022. Epub 2019 Dec 9.

Thrombolysis In Myocardial Infarction Study Group, Brigham and Women's Hospital, Cardiovascular Division, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.09.065DOI Listing
December 2019

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.

Diabetes Care 2020 02 16;43(2):468-475. Epub 2019 Dec 16.

Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc19-1476DOI Listing
February 2020

Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial.

Circulation 2019 12 9;140(24):2044-2046. Epub 2019 Dec 9.

Department of Cardiology, Akershus University Hospital, Lørenskog, Norway (J.B.S., P.L.M., M.N.L., T.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.041991DOI Listing
December 2019

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.

Circulation 2020 Feb 11;141(8):616-623. Epub 2019 Nov 11.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., F.K.K., F.N., Y.G., R.P.G., M.S.S., C.T.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.043805DOI Listing
February 2020

Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".

Circulation 2019 10 28;140(18):e740-e741. Epub 2019 Oct 28.

TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.S.S., S.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042848DOI Listing
October 2019

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.

J Am Coll Cardiol 2019 10;74(17):2132-2146

The Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.08.1024DOI Listing
October 2019

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

N Engl J Med 2019 11 19;381(21):1995-2008. Epub 2019 Sep 19.

From the BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (J.J.V.M., M.C.P., K.F.D., P.S.J.); the Cardiovascular Division (S.D.S., A.S.D.) and the TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School (M.S.S.) - all in Boston; Section of Endocrinology, Yale University School of Medicine, New Haven, CT (S.E.I.); Rigshospitalet Copenhagen University Hospital (L.K.) and the Department of Cardiology, Gentofte University Hospital (M. Schou), Copenhagen; the Department of Medicine, Saarland University Hospital, Homburg-Saar, Germany (M.B.); Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City (M.N.K.); National University of Cordoba, Cordoba (F.A.M.), and the Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires (M.D.) - both in Argentina; Wroclaw Medical University, Wroclaw (P.P.), and the Department of Cardiology, Medical University of Lodz, Lodz (J.D.) - both in Poland; the Department of Cardiology, University of Minnesota, Minneapolis (I.S.A.); 2nd Department of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic (J.B.); the Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan (C.-E.C.); the Department of Cardiology, Medanta, Gurgaon, India (V.K.C.); the Department of Cardiology, University Medical Center and University of Groningen, Groningen, the Netherlands (R.A.B.); the 5th Department of Internal Medicine, Comenius University in Bratislava, Bratislava, Slovakia (A.D.); the Department of Cardiology, Shanghai Institute of Cardiovascular Disease and Zhongshan Hospital Fudan University, Shanghai, China (J.G.); Cumming School of Medicine and Libin Cardiovascular Institute, University of Calgary, Calgary, AB (J.G.H.), the Department of Cardiology, Montreal Heart Institute, Montreal (E.O.), and the Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto (S.V.) - all in Canada; Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria (T.K.); the Cardiovascular Division of Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan (M.K.); the Department of Molecular and Clinical Medicine and Cardiology, Sahlgrenska Academy (C.E.A.L.), and AstraZeneca (O.B., M. Sjöstrand, A.M.L.), Gothenburg, and the Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University (C.H.), Uppsala - all in Sweden; the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Instituto do Coracao, Hospital das Clinicas da Faculdade de Medicina, Universidade de São Paolo, São Paolo (J.C.N.); the Department of Internal Medicine, Tan Tao University, Tan Duc, Vietnam (P.N.V.); the Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow (S.T.); and the Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison (D.L.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911303DOI Listing
November 2019

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.

Circulation 2019 10 18;140(16):1308-1317. Epub 2019 Sep 18.

Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., R.P.G., K.I., M.L.O., S.D.W., M.S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.041998DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791781PMC
October 2019

SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply.

Lancet 2019 08;394(10198):560-561

TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)30699-3DOI Listing
August 2019

PCSK9 inhibitors: what we know, what we should have understood, and what is to come.

Authors:
Marc S Sabatine

Eur Heart J 2019 Jul 23. Epub 2019 Jul 23.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehz514DOI Listing
July 2019

Impact of ADCY9 Genotype on Response to Anacetrapib.

Circulation 2019 Jul 23. Epub 2019 Jul 23.

Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.041546DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749971PMC
July 2019

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.

J Am Coll Cardiol 2019 06;73(23):2961-2970

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: https://twitter.com/rgiugliano.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.03.513DOI Listing
June 2019

Correctly understanding the diabetes data in FOURIER.

Diabetes Obes Metab 2019 10 4;21(10):2342-2343. Epub 2019 Jul 4.

Departments of Medicine and Nutritional Sciences, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13812DOI Listing
October 2019

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.

N Engl J Med 2019 05;380(19):1881-1882

Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1902837
Publisher Site
http://dx.doi.org/10.1056/NEJMc1902837DOI Listing
May 2019

Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply.

JAMA Cardiol 2019 06;4(6):600-601

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2019.1200DOI Listing
June 2019

Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.

Eur J Heart Fail 2019 04 18;21(4):462-470. Epub 2019 Feb 18.

Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458082PMC
April 2019

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.

Circulation 2019 01;139(3):366-375

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (B.M.S., E.A.B., A.Q., S.A.M., K.I., M.P.B., C.T.R., M.S.S., S.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038341DOI Listing
January 2019

PCSK9 inhibitors: clinical evidence and implementation.

Authors:
Marc S Sabatine

Nat Rev Cardiol 2019 03;16(3):155-165

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41569-018-0107-8
Publisher Site
http://dx.doi.org/10.1038/s41569-018-0107-8DOI Listing
March 2019

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

N Engl J Med 2019 01 10;380(4):347-357. Epub 2018 Nov 10.

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1812389DOI Listing
January 2019

Opportunities and Challenges in Mendelian Randomization Studies to Guide Trial Design.

JAMA Cardiol 2018 10;3(10):967

Deputy Editor, Cardiology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2018.2863DOI Listing
October 2018

WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.

Am J Cardiol 2018 Aug 16. Epub 2018 Aug 16.

Department of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjcard.2018.08.020DOI Listing
August 2018

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

N Engl J Med 2018 09 26;379(12):1107-1117. Epub 2018 Aug 26.

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston (E.A.B., S.D.W., J.K., K.I., A.Q., M.P.B., C.T.R., M.S.S., B.M.S.); the Cardiovascular Division, University of Texas Southwestern Medical Center, Dallas (D.K.M.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); the Department of Medicine, University of Minnesota, Minneapolis (C.L.F.); the Partners Clinical Research Centre, Nassau, Bahamas (C.B.); the Department of Cardiology, Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland (A.B.); Cardiolink Clinical Trials, Monterrey, Mexico (A.G.-C.); McMaster University, Brampton, ON (M.G.), and the Division of Endocrinology and Metabolism, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.) - both in Canada; MedStar Health Research Institute, Hyattsville, MD (N.J.W.); the Cardiology Department, Auckland City Hospital, Auckland, New Zealand (H.D.W.); Eisai, Woodcliff Lake, NJ (T.P., B.F., W.M., C.P., S.D.); National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (A.C.K.); and the Translational Research Institute for Metabolism and Diabetes, Florida Hospital and the Sanford-Burnham Institute, Winter Park (S.R.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1808721DOI Listing
September 2018

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.

JAMA Cardiol 2018 09;3(9):823-828

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://cardiology.jamanetwork.com/article.aspx?doi=10.1001/j
Publisher Site
http://dx.doi.org/10.1001/jamacardio.2018.2258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233651PMC
September 2018

Clinical benefits of evolocumab appear less than hoped - Authors' reply.

Lancet 2018 03;391(10124):934-935

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30529-4DOI Listing
March 2018

Inflammatory and Cholesterol Risk in the FOURIER Trial.

Circulation 2018 07 12;138(2):131-140. Epub 2018 Mar 12.

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (E.A.B., R.P.G., J.-G.P., S.A.M., M.S.S.).

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.0
Publisher Site
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034032DOI Listing
July 2018

Pharmacogenetics and the Promise of Personalized Medicine.

Authors:
Marc S Sabatine

JAMA Cardiol 2018 05;3(5):408

Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2018.0586DOI Listing
May 2018

Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.

J Am Coll Cardiol 2018 02;71(5):489-496

Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar and Dutch Network for Cardiovascular Research (WCN), the Netherlands; Department of Cardiology, CWZ Hospital, Nijmegen, the Netherland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2017.11.050DOI Listing
February 2018

DECLARE-TIMI 58: Participants' baseline characteristics.

Diabetes Obes Metab 2018 05 14;20(5):1102-1110. Epub 2018 Feb 14.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13217DOI Listing
May 2018

Questioning the safety and benefits of evolocumab - Authors' reply.

Lancet Diabetes Endocrinol 2018 01;6(1):11-12

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-8587(17)30403-5DOI Listing
January 2018

Cognitive Function in a Randomized Trial of Evolocumab.

N Engl J Med 2017 11;377(20):1997

Warren Alpert Medical School of Brown University, Providence, RI

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1712102DOI Listing
November 2017

Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.

Circulation 2018 02 30;137(7):684-692. Epub 2017 Oct 30.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (I.C., D.A.M., D.L.B., B.S.S., E.L.G., E.B., M.S.S., M.P.B.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.031062DOI Listing
February 2018

Evolocumab in Patients with Cardiovascular Disease.

N Engl J Med 2017 08;377(8):787-8

Oslo University Hospital, Oslo, Norway

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1708587DOI Listing
August 2017